The newly established “External Innovation” Team at LEO Pharma, a Denmark-based global leader in medical dermatology, is actively scouting and sourcing new partnering or in-licensing opportunities within medical dermatology. Specifically, the team is interested in novel opportunities that modulate immuno-inflammatory targets/pathways with rationale for rare or common skin disorders, including but not limited to the treatment of eczema, epidermolysis bullosa, bullous pemphigoid, rosacea, hidradenitis suppurativa, alopecia areata, vitiligo and melasma.
Approaches...